Showing results (11-20 of 26) with videos related to
Sort By:
Pageof 3
Journal of Environmental Management|March 17, 2025
Long-term assessment of hydropeaking and cumulative impacts on sediment transport, grain size dynamics, channel stability and water resource managementBinh Quang Nguyen, Sameh A Kantoush, Thanh-Nhan-Duc Tran, et al.Cancer Science|April 14, 2019
Anti-FIRΔexon2, a splicing variant form of PUF60, autoantibody is detected in the sera of esophageal squamous cell carcinomaSohei Kobayashi, Takaki Hiwasa, Takayuki Ishige, et al.Cancer Science|December 11, 2020
Anti-FIRΔexon2 autoantibody as a novel indicator for better overall survival in gastric cancerSohei Kobayashi, Takaki Hiwasa, Takayuki Ishige, et al.BMC Cancer|April 18, 2023
Analysis of patients with colorectal cancer shows a specific increase in serum anti-ING1 autoantibody levelsTakahiro Arasawa, Takaki Hiwasa, Akiko Kagaya, et al.Oncotarget|October 21, 2016
Anti-FIRs (PUF60) auto-antibodies are detected in the sera of early-stage colon cancer patientsSohei Kobayashi, Tyuji Hoshino, Takaki Hiwasa, et al.Journal of Clinical Laboratory Analysis|November 15, 2023
Combinational antibody detection approach increases the clinical validity of colorectal cancer screeningSohei Kobayashi, Takaki Hiwasa, Kouichi Kitamura, et al.Oncotarget|May 26, 2018
Disturbed alternative splicing of FIR (PUF60) directed cyclin E overexpression in esophageal cancersYukiko Ogura, Tyuji Hoshino, Nobuko Tanaka, et al.Proteomics. Clinical Applications|January 20, 2018
Assessment by Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry of the Effects of Preanalytical Variables on Serum Peptidome Profiles Following Long-Term Sample StorageSachio Tsuchida, Mamoru Satoh, Hiroshi Umemura, et al.Oncogenesis|February 20, 2020
Post-transcriptional regulation of BRG1 by FIRΔexon2 in gastric cancerGuzhanuer Ailiken, Kouichi Kitamura, Tyuji Hoshino, et al.International Journal of Molecular Sciences|December 23, 2023
The Link of mRNA and rRNA Transcription by PUF60/FIR through TFIIH/P62 as a Novel Therapeutic Target for CancerKouichi Kitamura, Tyuji Hoshino, Atsushi Okabe, et al.Pageof 3